Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases-Reference-Cited by-同舟云学术

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Published:2018-12 Issue:12 Volume:16 Page:1937-1946.e8
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Dreesen Erwin^ORCID,Verstockt Bram^ORCID,Bian Sumin,de Bruyn Magali^ORCID,Compernolle Griet,Tops Sophie,Noman Maja,Van Assche Gert,Ferrante Marc,Gils Ann,Vermeire Séverine

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference21 articles.

1. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases;Soler;J Pharmacol Exp Ther,2009

2. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

3. Vedolizumab as induction and maintenance therapy for Crohn’s disease;Sandborn;N Engl J Med,2013

4. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed;Sands;Gastroenterology,2014

5. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease;Vande Casteele;Gastroenterology,2015

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

2. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab;Inflammatory Bowel Diseases;2024-07-02

3. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

4. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

5. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05